"Sodium" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
| Descriptor ID |
D012964
|
| MeSH Number(s) |
D01.268.549.750 D01.268.557.650 D01.552.528.850 D01.552.547.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sodium".
Below are MeSH descriptors whose meaning is more specific than "Sodium".
This graph shows the total number of publications written about "Sodium" by people in this website by year, and whether "Sodium" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 15 | 27 | 42 |
| 2018 | 14 | 26 | 40 |
| 2019 | 5 | 10 | 15 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 4 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Sodium" by people in Profiles.
-
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review. Rheumatology (Oxford). 2021 10 02; 60(10):4530-4537.
-
Updated best practice statements regarding sodium-glucose cotransporter 2 inhibitors and serum potassium levels. Am J Health Syst Pharm. 2021 07 22; 78(15):1369-1370.
-
Considerations for best practices related to sodium-glucose cotransporter-2 inhibitors and serum potassium levels. Am J Health Syst Pharm. 2021 07 22; 78(15):1367-1368.
-
Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Kardiol Pol. 2021; 79(9):1048-1049.
-
Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Author's reply. Kardiol Pol. 2021; 79(9):1050-1051.
-
Sodium Toxicity in the Nutritional Epidemiology and Nutritional Immunology of COVID-19. Medicina (Kaunas). 2021 Jul 22; 57(8).
-
Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K. Diabetes Res Clin Pract. 2021 Aug; 178:108955.
-
Serum sodium alterations in SARS CoV-2 (COVID-19) infection: impact on patient outcome. Eur J Endocrinol. 2021 May 28; 185(1):137-144.
-
Dysnatremia is a Predictor for Morbidity and Mortality in Hospitalized Patients with COVID-19. J Clin Endocrinol Metab. 2021 05 13; 106(6):1637-1648.
-
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulm Pharmacol Ther. 2021 08; 69:102035.